Drug Disposition and Dynamics

About Drug Disposition & Dynamics

Understanding the time course of drug in the body is a critical element in the development of dosage regimens (how much drug to give how often and by what route). The development and application of mathematical models to describe this process and its interface with drug action is a critical step in the development of new drugs, as well as improving the use of existing agents.

In addition, understanding the processes by which drugs are absorbed, metabolized and eliminated are key to understanding drug effects after administration. Such knowledge can allow clinicians and scientists to anticipate and manage drug interactions and adverse effects, while maximizing the desired therapeutic effects. Researchers can also use these tools to gain an understanding of the fundamental mechanisms of disease.

Faculty of the Division of Pharmaceutics and Translational Therapeutics are actively engaged in research in this area at the molecular, biochemical, cellular, and whole body level.

Research in Drug Disposition & Dynamics

Dr. Peter Veng-Pedersen's research group’s main investigational areas include the pharmacokinetic and pharmacodynamic (PK/PD) mechanisms of erythropoietin in pre-mature, very low birth weight babies, the PK/PD of the insulin-glucose system in diabetic and pre-diabetic subjects as relating to prediction of the development of diabetes, and the in-vivo kinetic assessment and optimization of drug delivery.

Dr. Guohua An's research interest include building mechanism-based pharmacokinetic and pharmacodynamic modeling of small molecules (such as tysosine kinase inhibitors) and large molecules (such as Epo), understanding the mechanisms of poor brain penetration and offering novel approaches to overcome it and evaluating the transporter- and enzyme-based herbal-drug interactions.